168 related articles for article (PubMed ID: 34866084)
21. Antineoplastic effects of pharmacological inhibitors of aurora kinases in CSF3R
Parducci NS; Garnique ADMB; Lima K; Carlos JAEG; Fonseca NP; de Miranda LBL; de Almeida BO; Rego EM; Traina F; Machado-Neto JA
Blood Cells Mol Dis; 2024 Jan; 104():102799. PubMed ID: 37839173
[TBL] [Abstract][Full Text] [Related]
22. Successful Allogeneic Stem Cell Transplantation with Ruxolitinib Maintenance Therapy for
Ye P; Lin Q; Jin M; Gu X; Lu Y
Turk J Haematol; 2023 Feb; 40(1):73-74. PubMed ID: 36510384
[No Abstract] [Full Text] [Related]
23. Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization.
Maxson JE; Luty SB; MacManiman JD; Abel ML; Druker BJ; Tyner JW
J Biol Chem; 2014 Feb; 289(9):5820-7. PubMed ID: 24403076
[TBL] [Abstract][Full Text] [Related]
24. CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis.
Zhang X; Ghiuzeli C; Jou E; Hsu P; Kolitz J; Brody JP
Leuk Res Rep; 2022; 17():100334. PubMed ID: 35795468
[TBL] [Abstract][Full Text] [Related]
25. CSF3R is mutated in chronic neutrophilic leukemia and atypical CML.
Cancer Discov; 2013 Jul; 3(7):OF23. PubMed ID: 23847367
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
Dao KT; Gotlib J; Deininger MMN; Oh ST; Cortes JE; Collins RH; Winton EF; Parker DR; Lee H; Reister A; Schultz ; Savage S; Stevens ; Brockett C; Subbiah N; Press RD; Raess PW; Cascio M; Dunlap J; Chen Y; Degnin C; Maxson JE; Tognon CE; Macey T; Druker BJ; Tyner JW
J Clin Oncol; 2020 Apr; 38(10):1006-1018. PubMed ID: 31880950
[TBL] [Abstract][Full Text] [Related]
27. Myeloid Disease with the CSF3R T618I Mutation after CLL.
Couto ME; Bizarro S; Sousa D; Domingues N; Oliveira I; Martins G; Teixeira MR; Mariz M
Case Rep Hematol; 2020; 2020():6670965. PubMed ID: 33414971
[TBL] [Abstract][Full Text] [Related]
28. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.
Pardanani A; Lasho TL; Laborde RR; Elliott M; Hanson CA; Knudson RA; Ketterling RP; Maxson JE; Tyner JW; Tefferi A
Leukemia; 2013 Sep; 27(9):1870-3. PubMed ID: 23604229
[TBL] [Abstract][Full Text] [Related]
29. Genomics of chronic neutrophilic leukemia.
Maxson JE; Tyner JW
Blood; 2017 Feb; 129(6):715-722. PubMed ID: 28028025
[TBL] [Abstract][Full Text] [Related]
30. A CSF3R T618I Mutation in a Patient with Chronic Neutrophilic Leukemia and Severe Bleeding Complications.
Mitsumori T; Komatsu N; Kirito K
Intern Med; 2016; 55(4):405-7. PubMed ID: 26875968
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
Ouyang Y; Qiao C; Chen Y; Zhang SJ
Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
[TBL] [Abstract][Full Text] [Related]
32. Eighty-year-old man with rare chronic neutrophilic leukemia caused by
Li YP; Chen N; Ye XM; Xia YS
World J Clin Cases; 2020 Dec; 8(24):6337-6345. PubMed ID: 33392315
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and impact of colony stimulating factor 3 receptor (CSF3R) mutations among Egyptian acute myeloid leukemia patients.
Aref S; El-Ghonemy M; Abouzeid T; El-Sabbagh A; El-Baiomy M
Leuk Res; 2014 Jun; 38(6):722-5. PubMed ID: 24746896
[TBL] [Abstract][Full Text] [Related]
34. Anti-inflammatory effects of ruxolitinib on chronic neutrophilic leukemia harboring
Sahara N; Yokoyama K; Matsunaga T; Kitahara S; Fujii T; Kobayashi S; Yusa N; Shimizu E; Imoto S; Tojo A; Ohno N
Leuk Res Rep; 2022; 18():100348. PubMed ID: 36119729
[TBL] [Abstract][Full Text] [Related]
35. Clonal evolution in a chronic neutrophilic leukemia patient.
Zhang QG; Wang J; Gong WY; Jing QC
Hematology; 2019 Dec; 24(1):455-458. PubMed ID: 31076019
[TBL] [Abstract][Full Text] [Related]
36. Chronic neutrophilic leukemia 2014: Update on diagnosis, molecular genetics, and management.
Elliott MA; Tefferi A
Am J Hematol; 2014 Jun; 89(6):651-8. PubMed ID: 24845374
[TBL] [Abstract][Full Text] [Related]
37. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
38. What's different about atypical CML and chronic neutrophilic leukemia?
Dao KH; Tyner JW
Hematology Am Soc Hematol Educ Program; 2015; 2015():264-71. PubMed ID: 26637732
[TBL] [Abstract][Full Text] [Related]
39. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.
Tefferi A; Thiele J; Vannucchi AM; Barbui T
Leukemia; 2014 Jul; 28(7):1407-13. PubMed ID: 24441292
[TBL] [Abstract][Full Text] [Related]
40. The molecular genetics of chronic neutrophilic leukaemia: defining a new era in diagnosis and therapy.
Elliott MA; Tefferi A
Curr Opin Hematol; 2014 Mar; 21(2):148-54. PubMed ID: 24335708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
